1-4 of 4
Kristi Elkins
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate

Shweta Singh, Laura Serwer, Amy DuPage, Kristi Elkins, Niharika Chauhan, Matthew Ravn, Fritz Buchanan, Leyu Wang, Michael Krimm, Ken Wong, Jason Sagert, Kimberly Tipton, Stephen J. Moore, Yuanhui Huang, Andrew Jang, Eric Ureno, Adam Miller, Sarah Patrick, Shanti Duvur, Shouchun Liu, Olga Vasiljeva, Yingchun Li, Tracy Henriques, Ilaria Badagnani, Shawn Jeffries, Siew Schleyer, Rob Leanna, Claus Krebber, Sridhar Viswanathan, Luc Desnoyers, Jonathan Terrett, Marcia Belvin, Susan Morgan-Lappe, W. Michael Kavanaugh, Jennifer Richardson
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (8): 1326–1336.
https://doi.org/10.1158/1535-7163.MCT-21-0193
Published: 02 August 2022
View article titled, Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate
Open the PDF for Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate in another window
Includes: Supplementary data
Journal Articles

DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma

Dongwei Li, Kirsten Achilles Poon, Shang-Fan Yu, Randall Dere, MaryAnn Go, Jeffrey Lau, Bing Zheng, Kristi Elkins, Dimitry Danilenko, Katherine R. Kozak, Pamela Chan, Josefa Chuh, Xiaoyan Shi, Denise Nazzal, Franklin Fuh, Jacqueline McBride, Vanitha Ramakrishnan, Ruth de Tute, Andy Rawstron, Andrew S. Jack, Rong Deng, Yu-Waye Chu, David Dornan, Marna Williams, William Ho, Allen Ebens, Saileta Prabhu, Andrew G. Polson
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (7): 1255–1265.
https://doi.org/10.1158/1535-7163.MCT-12-1173
Published: 07 July 2013
View article titled, DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma
Open the PDF for DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma in another window
Includes: Supplementary data
Journal Articles

FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma

Kristi Elkins, Bing Zheng, MaryAnn Go, Dionysos Slaga, Changchun Du, Suzie J. Scales, Shang-Fan Yu, Jacqueline McBride, Ruth de Tute, Andy Rawstron, Andrew S. Jack, Allen Ebens, Andrew G. Polson
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (10): 2222–2232.
https://doi.org/10.1158/1535-7163.MCT-12-0087
Published: 09 October 2012
View article titled, FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma
Open the PDF for FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates

Bing Zheng, Reina N. Fuji, Kristi Elkins, Shang-Fan Yu, Franklin K. Fuh, Josefa Chuh, Christine Tan, Jo-Anne Hongo, Helga Raab, Katherine R. Kozak, Marna Williams, Elena McDorman, Dan Eaton, Allen Ebens, Andrew G. Polson
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (10): 2937–2946.
https://doi.org/10.1158/1535-7163.MCT-09-0369
Published: 12 October 2009
View article titled, <em>In vivo</em> effects of targeting CD79b with antibodies and antibody-drug conjugates
Open the PDF for <em>In vivo</em> effects of targeting CD79b with antibodies and antibody-drug conjugates in another window